Thursday, March 28, 2013
Researchers at The University of Texas MD Anderson Cancer Center have determined why many cancer vaccines fail to elicit a
robust T cell response-the cells hover near the vaccination site instead of
migrating to the tumor.1 The surprisingly simple solution is
switching the vaccine formulation to a different carrier.
Failure to launch
Overwijk's team vaccinated a mouse model
for melanoma with a short fragment of the melanoma antigen silver homolog (SILV;
in a solution of incomplete Freund's
a commonly used mineral oil-based carrier.
Cancer and beyond
Benjamin Chen, executive chairman of Immune Targeting Systems Ltd., said Overwijk's findings are potentially relevant to a
T cell-targeted vaccines for cancer and possibly other indications.
Osherovich, L. SciBX 6(12); doi:10.1038/scibx.2013.280
Published online March 28, 2013
1. Hailemichael, Y. et
al. Nat. Med.; published online March 3, 2013; doi:10.1038/nm.3105
Contact: Willem W. Overwijk, The University of Texas MD Anderson Cancer
Center, Houston, Texas
2. van Duikeren, S. et
al. J. Immunol. 189, 3397-3403 (2012)
AND INSTITUTIONS MENTIONED
Dendreon Corp. (NASDAQ:DNDN), Seattle, Wash.
Immune Targeting Systems Ltd., London, U.K.
ISA Pharmaceuticals B.V., Leiden, the Netherlands
Leiden University Medical Center, Leiden, the Netherlands
The University of Texas MD Anderson Cancer Center,